Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Stocks making the biggest moves premarket: Kohl's, Casey's General Stores, Vertex Pharmaceuticals and more
Check out the companies making headlines before the bell: Kohl’s — Shares tumbled 9% after the retailer posted disappointing fourth-quarter revenue of $4.97 billion, below the LSEG consensus of $5.03 billion. On the other hand, fourth quarter earnings of $1.07 per share exceeded the expected 85 cents per share. Casey’s General Stores — The convenience store chain shed 2.6% following its third-quarter revenue miss. Casey’s General Stores reported revenue of $3.92 billion, short of the $4.04 billion consensus estimate, per FactSet. Earnings, however, topped expectations. Taiwan Semiconductor — The Taiwanese chipmaker’s shares inched up about 1% in premarket after the company reported a 30% increase in sales over the first two months of the year. Vail Resorts — The ski resort’s stock price slid 1.1% after reporting earnings of $5.87 per share on $1.08 billion in revenue, while analysts polled by LSEG expected $6.10 per share on $1.11 billion in revenue. The company also lowered its guidance “due to the persistent, historically challenging weather conditions in the Rockies.” Hewlett Packard Enterprise — Shares of the technology company rose 1%. HPE earned 65 cents per share, on an adjusted basis, for its first quarter. That exceeded analysts’ estimate of 59 cents per share, according to LSEG. The company’s $9.30 billion in revenue fell slightly short of the $9.33 billion expected, meanwhile. Vertex Pharmaceuticals — Vertex Pharmaceuticals shares advanced more than 6% after the biotech company said its drug met its goals in a late-stage trial for IgA nephropathy, a chronic condition that can lead to kidney failure. — CNBC’s Michelle Fox, Yun Li and Pia Singh contributed reporting